Financials in USD. Standardized financial statements.
A compact view of how Kobayashi Pharmaceutical Co., Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $165.89B | $165.60B | $173.46B | $166.26B | $155.25B | $150.51B | $168.05B | $167.48B | $156.76B | $152.65B |
| Revenue Growth? | +0.2% | -4.5% | +4.3% | +7.1% | +3.1% | -10.4% | +0.3% | +6.8% | +2.7% | 0.0% |
| Cost of Revenue? | $86.38B | $78.00B | $77.08B | $73.93B | $66.48B | $65.25B | $64.70B | $64.36B | $61.24B | $62.80B |
| Gross Profit? | $79.51B | $87.60B | $96.38B | $92.33B | $88.77B | $85.27B | $103.35B | $103.12B | $95.52B | $89.85B |
| Gross Margin? | +47.9% | +52.9% | +55.6% | +55.5% | +57.2% | +56.6% | +61.5% | +61.6% | +60.9% | +58.9% |
| Operating Expenses? | $64.65B | $62.74B | $70.60B | $65.66B | $62.70B | $59.32B | $76.98B | $76.82B | $72.59B | $69.60B |
| Operating Income? | $14.86B | $24.86B | $25.78B | $26.67B | $26.07B | $25.94B | $26.36B | $26.29B | $22.93B | $18.91B |
| EBITDA? | $23.61B | $21.96B | $33.65B | $31.86B | $30.79B | $29.91B | $30.95B | $29.59B | $26.33B | $22.41B |
| Income Before Tax | $3.75B | $13.91B | $27.56B | $27.95B | $27.64B | $26.64B | $26.80B | $25.30B | $22.57B | $20.88B |
| Income Tax Expense | $83.07M | $3.84B | $7.22B | $7.93B | $7.92B | $7.43B | $7.67B | $7.28B | $6.71B | $5.62B |
| Net Income? | $3.66B | $10.07B | $20.34B | $20.02B | $19.71B | $19.20B | $19.14B | $18.02B | $15.86B | $15.33B |
| EPS? | $48.62 | $135.42 | $268.16 | $259.63 | $252.36 | $245.71 | $244.08 | $228.04 | $201.31 | $191.13 |
| Diluted EPS? | $48.62 | $135.42 | $268.16 | $259.59 | $252.36 | $245.71 | $244.08 | $227.95 | $201.03 | $191.14 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality